iifl-logo

Ishita Drugs & Industries Ltd Board Meeting

Add as a Preferred Source on Google
₹74.01
(-5.72%)
Nov 20, 2026|04:01:00 PM

Ishita Drugs CORPORATE ACTIONS

22/11/2025calendar-icon
22/11/2026calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting3 Nov 202628 Oct 2026
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2026. 2. Any other matter with permission of the Chair. Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026 alongwith limited review report issued by the statutory auditors of the Company. (As Per BSE Announcement Dated on:03.11.2026)
Board Meeting22 Sep 202618 Sep 2026
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/09/2026 inter alia to consider and approve 1. To consider and approve raising of funds by the Company by way of working capital and project term loan facilities and to approve the terms and conditions for the same. 2. Any other matter with permission of the Chair. we wish to inform you that the Board of Directors of Ishita Drugs and Industries Limited, held its meeting today i.e. Tuesday, 22nd September, 2026, has, Approved the borrowings from the HDFC Bank Limited. (As Per BSE Announcement Dated on:22.09.2026)
Board Meeting8 Aug 202631 Jul 2026
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2026. 2. Any other matter with permission of the Chair. Outcome of the Board meeting held on 08th August, 2026. (As per BSE Announcement dated on: 08.08.2026)
Board Meeting30 May 202623 May 2026
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve 1. To consider approve and take on records the Audited Financial Results of the Company for the quarter and year ended 31st March 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 33rd Annual General Meeting of the Company. 3. To consider the re-appointment of Internal Auditors of the Company for the year 2026-27. 4. To take on record Disclosure of Interest of Directors. 5. Any other matter with permission of the Chair. Outcome of Board Meeting held on 30th May, 2026. (As per BSE announcement dated on : 30.05.2026)
Board Meeting7 Feb 202630 Jan 2026
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 31st December 2025. 2. Any other matter with permission of the Chair. Unaudited Financial Results for the quarter ended 31st December, 2025 along with Limited review report issued by the statutory auditors of the Company (As Per BSE Announcement Dated on:07.02.2026)

Ishita Drugs: Related News

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.